SecBot SecBot
6-K ·Filed Sep 8, 2026

AZN

ASTRAZENECA PLC
BULLISH
Impact 7/10
Horizonweeks Processed2mo ago SEC0001654954-26-008150
Notable filing: 6-K
Actionable Insight ▲ Bullish

Traders should watch for initial prescription trends and label expansion updates (SERENA-4, CAMBRIA-1/2 trials). The accelerated approval de-risks the near-term commercial outlook, but OS data maturity and potential competitive oral SERD entries (e.g., Roche's giredestrant) are key medium-term catalysts to monitor.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+20
Entry
$160.04
T+0 close · Sep 8, 2026 · via day close
Latest settled
−0.89%
T+20 · $158.61 · next T+60 in 16d
Vs SPY
−2.61%
α at T+20
Latest observation
+17.03%
T+48 · FF3 residual α
  1. T+0 · Sep 8 $160.04entry
  2. T+1 · 2mo ago −1.94%α −1.47% · $156.94
  3. T+5 · 2mo ago +1.13%α +2.25% · $161.85
  4. T+20 · 6w ago −0.89%α −2.61% · $158.61
  5. T+49 · todayOpen
  6. T+60 · in 16d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

AstraZeneca announced FDA accelerated approval of Etcamah (camizestrant) in combination with a CDK4/6 inhibitor for 1st-line advanced HR-positive, HER2-negative breast cancer with an emergent ESR1 mutation. The approval, based on the SERENA-6 Phase III trial showing a 56% reduction in the risk of disease progression or death, expands AstraZeneca's breast cancer portfolio and represents the company's fourth FDA approval in breast cancer this year. This is a significant commercial catalyst for a large-market indication, though the accelerated approval pathway and immature overall survival data introduce some regulatory and competitive uncertainty.

Key Facts

  • FDA accelerated approval of Etcamah (camizestrant) + CDK4/6 inhibitor for 1st-line advanced HR+/HER2- breast cancer with emergent ESR1 mutation.
  • Approval based on SERENA-6 Phase III trial: 56% reduction in risk of disease progression or death (HR 0.44; p<0.00001; median PFS 16.0 vs 9.2 months).
  • Statistically significant PFS2 benefit: 25.7 vs 19.1 months (HR 0.63; p=0.00373).
  • OS data immature but trending in favor of Etcamah (HR 0.87; 95% CI 0.57-1.30).
  • ~30% of HR+ patients develop ESR1 mutations during 1st-line treatment before progression; ~37,000 US patients treated in 1st-line metastatic setting annually.
  • Etcamah already approved in >30 countries including EU, Japan, Canada, UK.
  • This is AstraZeneca's 10th FDA approval in 2026 and 4th in breast cancer alone.
  • FDA also concurrently approved a companion diagnostic ctDNA test for ESR1 mutations.

Financial Impact

Etcamah addresses a large addressable patient population (~30% of 37,000 US 1st-line HR+ metastatic patients, plus global >200,000 patients). As a first-in-class oral SERD with a novel ctDNA-guided switch strategy, peak sales potential is material to AstraZeneca's oncology revenue, though specific revenue figures were not disclosed.

revenuepipeline valuemarket share

Risk Factors

  • Accelerated approval may require confirmatory data; OS benefit not yet statistically significant.
  • Competition from other oral SERDs (e.g., Roche's giredestrant, Menarini's elacestrant) could limit market share.
  • Reimbursement and guideline adoption may take time; ctDNA testing infrastructure needed for patient selection.

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
80% bullish (35 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001654954-26-008150
Document: 0001654954-26-008150-index-headers.html0001654954-26-008150
Document: 0001654954-26-008150-index.html0001654954-26-008150
Document: 0001654954-26-008150.txt0001654954-26-008150

Track record

77 reports on AZN

Performance horizon

18 of 37 bullish or bearish reports moved the stock their way by T+5. Best: +20.72% at T+60 after the Aug 17, 2026 report. 28 of 37 went positive at some point.

Filters
  1. Nov 16, 2026today 6-K Bullish 6/10 Entry price pending
  2. Nov 16, 2026today 6-K Bullish 6/10 Entry $185.55 Now $184.02 −0.82% settles Nov 23
  3. Nov 16, 2026today 6-K Bullish 6/10 Entry $185.31 Now $184.02 −0.70% settles Nov 23
  4. Nov 16, 2026today 6-K Bullish 5/10 Entry $185.09 Now $184.02 −0.58% settles Nov 23
  5. Nov 4, 202611d ago Institutional Cluster Mixed 3/10 Entry $186.85 to $184.38 Now $184.02 −1.51% ▼ −1.32% −4.61% vs SPY
  6. Nov 2, 202614d ago 6-K Neutral 1/10 Entry $186.58 to $189.39 Now $184.02 −1.37% ▲ +1.51% +1.43% vs SPY
  7. Nov 2, 202614d ago 6-K Neutral 1/10 Entry $186.58 to $189.39 Now $184.02 −1.37% ▲ +1.51% +1.43% vs SPY
  8. Oct 30, 202617d ago 6-K Neutral 5/10 Entry $186.65 to $186.43 Now $184.02 −1.41% ▼ −0.12% +2.59% vs SPY
  9. Oct 27, 202620d ago 6-K Bullish 5/10 Entry $170.08 to $183.88 Now $184.02 +8.20% ▲ +8.11% +10.10% vs SPY
  10. Oct 22, 202625d ago 6-K Bullish 6/10 Entry $172.57 to $173.46 Now $184.02 +6.63% ▲ +0.51% −0.19% vs SPY
Showing 10 of 77

US Market Status

Market Closed · Opens Tue (< 1m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 9, 2026